Illustrative image – not actual.
Shanghai Fosun Pharmaceutical (Group) Co has emerged the highest bidder for KKR-backed Gland Pharma at a little over a billion dollars, and it’s looking to increase its research and manufacturing capacity.
Coming from behind in a closely fought race that saw US giant Baxter, and private equity fund Advent make firm offers in May 2016, Shanghai Fosun (Fosun Pharma) revised its offer last week to $1.27 billion. This was against the $1.1 billion offered by Baxter.
Final negotiations have been planned for June 2016 followed by a formal announcement.
